Videos

 

The Changing Landscape in CML Therapy: New Treatment Goals and Choices

Timothy Hughes, MD, FRACP, FRCPA
Head of the Department of Hematology at IMVS (RAH site)
Consultant Hematologist
Royal Adelaide Hospital
Australia
 

The Changing CML Treatment Paradigm

Giuseppe Saglio, MD, PhD
Professor of Hematology
University of Turin
Ospedale Mauriziano-Torino
Turin, Italy
 

Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients

Chrissy H.Y. van Beurden-Tan, MSc
Health Economist and PhD Candidate
Department of Hematology
Erasmus MC Cancer Institute
Rotterdam, Netherlands
 

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis

Abdallah Abou Zahr
Department of Leukemia
University of Texas MD Anderson
Cancer Center
Houston, Texas, United States
 

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD, PhD
Deputy Director and Chief Consultant
Senckenberg Institute of Pathology
Head of Hematopathology and Tumorpathology Section
University of Frankfurt
Frankfurt, Germany
 

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Denis-Claude Roy, MD
Professor of Medicine
Université de Montréal
Chief Executive Officer
CellCAN Regenerative Medicine and Cell
Therapy Network
Director of Research
Le CIUSSS de l’Est-de-l’Île-de-Montréal
Scientific Director
Centre of Excellence for Cellular Therapy
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
 

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

M. Lynn Savoie, MD, FRCPC
Clinical Associate Professor
Division of Hematology and Hematologic Malignancies
University of Calgary
Calgary, Alberta, Canada
 

Failure to Achieve Early Molecular Milestone within 3 Months is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Dennis Kim, MD, PhD, FRCP(C)
Associate Professor of Medicine
Department of Medicine
University of Toronto
Clinical Investigator
Department of Medical Oncology and Hematology
Princess Margaret Cancer Centre
University Health Network & Mount Sinai Hospital
Toronto, Ontario, Canada
 

Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib (RUX) with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis (MF): Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders – Research Consortium (MPD-RC)

Pierre Laneuville, MD, FRCP
Associate Professor of
Medicine and Oncology
McGill University Health Centre and Research Institute
Montreal, Quebec, Canada
 

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Pierre Laneuville, MD, FRCP
Associate Professor of
Medicine and Oncology
McGill University Health Centre and Research Institute
Montreal, Quebec, Canada
 

Treatment-Free Remission Accomplished by Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Kim, MD, PhD, FRCP(C)
Associate Professor of Medicine
Department of Medicine
University of Toronto
Clinical Investigator
Department of Medical Oncology and Hematology
Princess Margaret Cancer Centre
University Health Network & Mount Sinai Hospital
Toronto, Ontario, Canada
 

Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries

Christopher Hillis, MD, FRCPC
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada
 

Recent developments in the management of patients at risk of thromboembolism – from non-malignant to malignant conditions

Deborah Siegal, MD, MSc, FRCPC
Clinical Scholar, Department of Medicine
Investigator, Population Health Research Institute
McMaster University
Hamilton, Ontario, Canada
 

Results from ENESTop: Treatment-free remission following switch to Nilotinib in patients with chronic myeloid leukemia in chronic phase

Prof. Tim Hughes, MB.BS, MD, FRACP, FRCPA
Cancer Theme Leader
South Australian Health and Medical Research Institute (SAHMRI)
Beat Cancer Professor
University of Adelaide
Adelaide, South Australia
 

Prevention of thrombosis in patients with polycythemia vera treated with hydroxyurea plus phlebotomies or hydroxyurea alone

Alberto Alvarez-Larrán, MD
Department of Hematology
Hospital del Mar
Barcelona, Spain
 

Recent developments in the management of CML and their impact on Canadian clinical practice

Pierre Laneuville, MD, FRCP
Associate Professor of Medicine and Oncology
McGill University Health Centre and Research Institute
Montreal, Quebec, Canada
 

The management of ITP and SAA in the era of TPO agonists

Phillip Scheinberg, MD
Head, Clinical Hematology
Antônio Ermírio de Moraes Cancer Center
São José and Beneficência Portuguesa Hospital
São Paulo, Brazil
 

Recent evidence regarding the use of JAK inhibitors in the management of patients with MPNs

Ruben A. Mesa, MD, FACP
Chair, Division of Hematology and Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Professor of Medicine
Mayo Clinic College of Medicine
Arizona, USA
 

Molecular markers in MPNs and their prognostic value

Carlos Besses, MD, PhD
Department of Hematology
Hospital del Mar-IMIM
Barcelona, Spain
 

The emerging role of the TPO agonist eltrombopag in the treatment of thrombocytopenia in MDS and AML

Jaroslav F. Prchal, MD, FRCPC
Chief, Department of Oncology
St. Mary's Hospital Center
Associate Professor
Department of Medicine and Oncology
McGill University
Montreal, Quebec, Canada
 

Treatment-free remission as a new goal in chronic myeloid leukemia

Giuseppe Saglio, MD, PhD
Professor of Hematology
University of Turin
Ospedale Mauriziano-Torino
Turin, Italy
CML

Prediction for deeper molecular response after TKI treatment in CML patients

Dennis Kim, MD, FRCP(c)
Associate Professor, Faculty of Medicine
University of Toronto
Toronto, Ontario, Canada
MPN

The latest information on myeloproliferative neoplasms

Attilio Orazi, MD, FRCPath. (Angl.)
Weill Cornell Medical College
New York Presbyterian Hospital
New York, NY, USA
MPN

Combination therapy for patients with MPN

Vikas Gupta, MD, FRCPC, FRCPath
Associate Professor
Department of Medicine
University of Toronto
Cancer Clinical Research Unit (CCRU)
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
AML

Induction and consolidation

Karen Yee, MD, FRCPC
Cancer Clinic Research Unit
Princess Margaret Cancer Centre
University Health Network
Toronto, Ontario, Canada
MPN

Predictive values of next generation sequencing (NGS) in myeloproliferative neoplasms (MPNS)

Christopher Hillis, MD, FRCPC
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada
MPN

Long-term efficacy of pegylated Interferon in ET and PV

Shireen Sirhan
MD, FRCPC
Hematologist and Medical Oncologist
Montreal Jewish General Hospital
MPN

Pacritinib in myelofibrosis: Subgroup analysis of PERSIST-1

Shireen Sirhan
MD, FRCPC
Hematologist and Medical Oncologist
Montreal Jewish General Hospital
MPN

Long-term efficacy of PRM-151 in myelofibrosis

Shireen Sirhan
MD, FRCPC
Hematologist and Medical Oncologist
Montreal Jewish General Hospital